EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
Status:
RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment.
The main questions to answer are:
Safety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.
Phase:
PHASE1
Details
Lead Sponsor:
Peking University
Collaborators:
Everest Medicines (China) Co.,Ltd. Shanghai Cancer Centre